| Market Cap | 159.10M | P/E | - | EPS this Y | 38.30% | Ern Qtrly Grth | - |
| Income | -64.66M | Forward P/E | -2.11 | EPS next Y | 31.40% | 50D Avg Chg | 11.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
| Dividend | N/A | Price/Book | 1.93 | EPS next 5Y | - | 52W High Chg | -64.00% |
| Recommedations | 2.40 | Quick Ratio | 10.35 | Shares Outstanding | 29.84M | 52W Low Chg | 68.00% |
| Insider Own | 21.85% | ROA | -42.89% | Shares Float | 10.34M | Beta | -0.21 |
| Inst Own | 61.79% | ROE | -69.48% | Shares Shorted/Prior | 249.63K/386.84K | Price | 8.19 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 98,716 | Target Price | 10.33 |
| Oper. Margin | - | Earnings Date | - | Volume | 8,781 | Change | -0.12% |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| JMP Securities | Market Outperform | Aug 9, 24 |
| Leerink Partners | Outperform | Jul 3, 24 |
| Evercore ISI Group | In-Line | May 16, 24 |
| JMP Securities | Market Outperform | Apr 2, 24 |
| Oppenheimer | Perform | Apr 1, 24 |
| Leerink Partners | Market Perform | Feb 13, 24 |
| Evercore ISI Group | In-Line | Feb 12, 24 |
| Oppenheimer | Perform | Feb 12, 24 |
| JMP Securities | Market Perform | Feb 12, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Zakrzewski Joseph S | Director Director | Jan 18 | Sell | 19.1141 | 100,000 | 1,911,410 | 405,880 | 01/19/24 |
| Aziz Kabeer | Director Director | Jan 16 | Sell | 19.65 | 100,000 | 1,965,000 | 377,542 | 01/18/24 |
| Adjuvant Global Health Technol... | Director Director | Jan 16 | Sell | 19.65 | 100,000 | 1,965,000 | 377,542 | 01/18/24 |
| Readnour Robin Shane | Director Director | Jan 12 | Sell | 21.92 | 1,425 | 31,236 | 485,073 | 01/17/24 |
| Readnour Robin Shane | Director Director | Jan 10 | Sell | 21.93 | 3,669 | 80,461 | 485,792 | 01/12/24 |
| Krause Kevin Michael | Chief Strategy Offic.. Chief Strategy Officer | Jan 09 | Sell | 20.14 | 7,417 | 149,378 | 1,914 | 01/11/24 |
| Krause Kevin Michael | Chief Strategy Offic.. Chief Strategy Officer | Jan 09 | Option | 3.51 | 7,417 | 26,034 | 9,331 | 01/11/24 |
| Krause Kevin Michael | Chief Strategy Offic.. Chief Strategy Officer | Jan 02 | Sell | 20.12 | 2,583 | 51,970 | 1,914 | 01/04/24 |
| Krause Kevin Michael | Chief Strategy Offic.. Chief Strategy Officer | Jan 02 | Option | 0.42 | 2,583 | 1,085 | 4,497 | 01/04/24 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Jan 02 | Sell | 20.0945 | 2,777 | 55,802 | 2,130 | 01/04/24 |
| Adjuvant Global Health Technol... | Director Director | Nov 14 | Sell | 16.15 | 1,810 | 29,231 | 393,449 | 11/16/23 |
| Aziz Kabeer | Director Director | Nov 14 | Sell | 16.15 | 1,810 | 29,231 | 393,449 | 11/16/23 |
| Aziz Kabeer | Director Director | Sep 29 | Sell | 16.18 | 104,773 | 1,695,227 | 393,737 | 10/03/23 |
| Adjuvant Global Health Technol... | Director Director | Sep 29 | Sell | 16.18 | 104,773 | 1,695,227 | 393,737 | 10/03/23 |
| Adjuvant Global Health Technol... | Director Director | Sep 27 | Sell | 16.09 | 9,357 | 150,554 | 410,403 | 09/29/23 |
| Aziz Kabeer | Director Director | Sep 27 | Sell | 16.09 | 9,357 | 150,554 | 410,403 | 09/29/23 |
| Aziz Kabeer | Director Director | Aug 23 | Sell | 16 | 400 | 6,400 | 411,893 | 09/15/23 |
| Adjuvant Global Health Technol... | Director Director | Aug 23 | Sell | 16 | 400 | 6,400 | 411,893 | 09/15/23 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner 10% Owner | Aug 18 | Buy | 9.00 | 1,777,778 | 16,000,002 | 5,135,683 | 08/22/23 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | May 15 | Buy | 5.377 | 10,000 | 53,770 | 1,015,766 | 05/15/23 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Nov 10 | Sell | 15.18 | 4,436 | 67,338 | 4,907 | 11/14/22 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Nov 08 | Sell | 15.8 | 17,166 | 271,223 | 4,907 | 11/09/22 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Nov 03 | Sell | 16.02 | 35,196 | 563,840 | 4,907 | 11/07/22 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Oct 31 | Sell | 15.23 | 4,232 | 64,453 | 4,907 | 11/02/22 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Oct 27 | Sell | 15.22 | 2,607 | 39,679 | 4,907 | 10/28/22 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Oct 24 | Sell | 15.79 | 9,350 | 147,636 | 4,907 | 10/26/22 |
| Easom Eric | Chief Executive Offi.. Chief Executive Officer | Oct 20 | Sell | 16.7 | 21,244 | 354,775 | 4,907 | 10/24/22 |
| RA CAPITAL MANAGEMENT, L.P. | 10% Owner 10% Owner | Jul 26 | Buy | 7.81 | 23,219 | 181,340 | 3,771,608 | 07/28/22 |
| Adjuvant Global Health Technol... | 10% Owner 10% Owner | Mar 29 | Buy | 15 | 166,666 | 2,499,990 | 2,210,735 | 06/24/22 |
| Readnour Robin Shane | Director Director | Mar 29 | Buy | 15 | 153,334 | 2,300,010 | 487,592 | 03/31/22 |
| Aziz Kabeer | Director Director | Mar 29 | Buy | 15 | 166,666 | 2,499,990 | 2,210,735 | 03/31/22 |